SCHEMBL21484792

SCHEMBL21484792

Cc1cc(/C=C(\C#N)C(=O)Nc2nc(-c3ccccc3)cs2)ccc1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.53
ERBB2 P04626 4/20 0.53
MEN1 O00255 5/20 0.51
MAPT P10636 5/20 0.51
KMT2A Q03164 5/20 0.51
LMNA P02545 4/20 0.51
ALDH1A1 P00352 4/20 0.51
MAPK1 P28482 4/20 0.51
KDM4E B2RXH2 3/20 0.51
RGS12 O14924 3/20 0.51
GMNN O75496 3/20 0.51
TP53 P04637 3/20 0.51
CYP1A2 P05177 3/20 0.51
CYP3A4 P08684 3/20 0.51
ALOX15 P16050 3/20 0.51
ALOX12 P18054 3/20 0.51
NFKB1 P19838 3/20 0.51
CYP2C19 P33261 3/20 0.51
BLM P54132 3/20 0.51
GNAI1 P63096 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21484629 0.91 EGFR (0.62) EGFRERBB2MEN1MAPTKMT2A
SCHEMBL21484600 0.90 MRE11 (0.58) EGFRERBB2MAPTLMNAALDH1A1
SCHEMBL21484912 0.89 MEN1 (0.52) EGFRERBB2MEN1MAPTKMT2A
SCHEMBL21484888 0.89 EGFR (0.60) EGFRERBB2MEN1MAPTKMT2A
SCHEMBL21484699 0.89 MRE11 (0.57) EGFRERBB2MEN1MAPTKMT2A
SCHEMBL21505433 0.89 EGFR (0.51) EGFRERBB2MEN1MAPTKMT2A
SCHEMBL28514954 0.89 EGFR (0.51) EGFRERBB2MEN1MAPTKMT2A
SCHEMBL21484882 0.89 EGFR (0.53) EGFRERBB2MEN1MAPTKMT2A
SCHEMBL21484916 0.89 CSNK2A1 (0.63) EGFRERBB2MEN1MAPTKMT2A
SCHEMBL21484777 0.88 MRE11 (0.51) EGFRERBB2MEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
CN-112313229-A Substituted aminothiazoles as inhibitors of nucleases 马萨里克大学 2021-02-02 CN disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
EP-3556755-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed
EP-3556755-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 EGFR 1661/4885ERBB2 2095/4885MEN1 1727/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 EGFR 1661/4885ERBB2 2095/4885MEN1 1727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.